Tissue-agnostic cancer drugs are antineoplastic drugs that treat cancers based on the mutations that they display, instead of the tissue type in which they appear.[1][2][3] Tissue-agnostic drugs that have been approved for medical use include Pembrolizumab, Larotrectinib, Selpercatinib, Entrectinib, and Pralsetinib.[2][4][5][6]
Pembrolizumab was approved by the US Food and Drug Administration in May 2017.[7]
Larotrectinib was approved by the FDA in November, 2018.[7]
Selpercatinib (LOXO-292) received priority review in September 2018[7] and was approved for medical use in the United States in May 2020.[8][9]
Entrectinib was approved for medical use in the United States in August 2019,[10][11] in Australia in May 2020,[12] and in the European Union in July 2020.[13]
Pralsetinib was approved for medical use in the United States in September 2020.[14][15]
Dabrafenib and Trametinib have been approved as tissue-agnostic drugs for solid tumors that are B-RAF positive. [16]
Tissue-agnostic cancer drugs that are under development as of May 2022[update] include Selitrectinib (Loxo-195) and anti-ERBB3 antibodies.[7]
This antineoplasticorimmunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |